ClinicalTrials.gg
CompletedNCT03409588Updated Feb 5, 2026

Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty

A Phase 2 interventional study of Adempas in Chronic Thromboembolic Disease (CTED) and Exercise Intolerance Post PEA Surgery, sponsored by University of Colorado, Denver. Completed at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by University of Colorado, Denver · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Study summary

This is an open label study of Riociguat in patients with continued exercise intolerance at least 6 months following pulmonary endarterectomy (PEA).

02

Conditions studied

  • Chronic Thromboembolic Disease (CTED)
  • Exercise Intolerance Post PEA Surgery

Keywords

  • Chronic Thromboembolic Disease
  • CTED
  • Treatment Post PEA surgery
03

In context

Lead sponsor

University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.

Of its 147 completed or terminated interventional studies of FDA-regulated products, 92 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients who underwent PTE or BPA for Chronic thromboembolic pulmonary hypertension (CTEPH) at least six months prior to screening and report ongoing subjective exercise limitation,
  • able to give consent
  • able to perform a exercise protocol

Exclusion criteria

Exclusion Criteria:

  • Patients with known Residual Pulmonary Hypertension (RPH) by RHC following PTE for CTEPH
  • ongoing PAH-specific vasodilator therapy
  • known to riociguat
  • a physical limitation to completing an exercise protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Study Drug

    Riociguat (Adempas) 0.5mg to 2.5 mg three time daily - oral medication

    Drug: Adempas

Interventions

  • DrugRiociguatStudies of RiociguatRiociguat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After obtaining baseline data, patients will be placed on oral riociguat at a dose of 0.5 mg TID which will be up titrated over two months to a maximum dose of 2.5 mg TID or maximum tolerated dose. After 3 months from onset of riociguat initiation, the University of California San Diego (UCSD) shortness of breath score, 6 Minute Walk Test (6MWD), and resting/exercise Right Heart Catheterization (RHC) will be repeated.

    Also known as: Riociguat

06

What researchers measure

Primary outcomes

  1. Change in mean pulmonary arterial pressure

    Measurements include mPAP (mean pulmonary arterial pressure) measured by right heart catheterization (RHC)

    Time frame: Baseline and 3 months

  2. Change in cardiac output

    Measurements include CO (cardiac output) mPAP/CO slope measured by right heart catheterization (RHC)

    Time frame: Baseline and 3 months

  3. Change in Pulmonary artery compliance

    Measurements include Pulmonary artery compliance measured by right heart catheterization (RHC)

    Time frame: Baseline and 3 months

Secondary outcomes

  1. Change in 6 minute walk test

    Measurements include change in 6 minute walk test (6 MWT) following 3 months of study drug

    Time frame: Baseline and 3 months

  2. Change in New York Heart Association (NYHA) functional class

    Measurements include Change in New York Heart Association (NYHA) functional class following 3 months of study drug

    Time frame: Baseline and 3 months

  3. Change in the University of California San Diego (UCSD) shortness of Breath Score

    Measurements include: Change in the University of California San Diego (UCSD) shortness of Breath Score following 3 months of study drug

    Time frame: Baseline and 3 months

07

Study locations

1 site
  • University of Colorado, Anschutz Medical Campus
    Aurora, Colorado 80045, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Jan 2026, 91 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2018
First posted
Jan 24, 2018
StartActual
Jun 13, 2018
Primary completionActual
Jan 26, 2026
CompletionActual
Jan 26, 2026
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03409588
Collaborators
Bayer
Responsible party
Sponsor
First posted
Jan 24, 2018
Start date
Jun 13, 2018
Primary completion
Jan 26, 2026
Completion
Jan 26, 2026
Last update
Feb 5, 2026

Study contacts

Todd Bull, MD
principal investigator · University of Colorado, Denver
Peter Sottile, MD
principal investigator · University of Colorado, Denver
William Cornwell, MD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Riociguat

Start the discussion